Get the Stockscreener App
36.78
0.77%
0.28
After Hours:
36.78
Agios Pharmaceuticals Inc stock is traded at $36.78, with a volume of 570.80K.
It is up +0.77% in the last 24 hours and up +3.96% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$36.50
Open:
$36.43
24h Volume:
570.80K
Relative Volume:
0.73
Market Cap:
$2.14B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
3.2377
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
+2.14%
1M Performance:
+3.96%
6M Performance:
+15.01%
1Y Performance:
-18.12%
1-Day Range:
$35.82
$37.18
1-Week Range:
$34.97
$37.32
52-Week Range:
$23.41
$62.58
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
36.78 | 2.07B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
HC Wainwright Issues Pessimistic Estimate for AGIO Earnings - MarketBeat
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells $315,091.02 in Stock - MarketBeat
611,098 Shares in Agios Pharmaceuticals, Inc. $AGIO Purchased by SCS Capital Management LLC - MarketBeat
Adage Capital Partners GP L.L.C. Raises Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals, Inc. $AGIO Shares Purchased by Boothbay Fund Management LLC - MarketBeat
Cutter Capital Management LP Trims Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Is Agios Pharmaceuticals Inc. stock technically oversold2025 Bull vs Bear & Real-Time Price Movement Reports - Lancaster City Council
What is the earnings history of Agios Pharmaceuticals Inc.Quarterly Trade Summary & AI Driven Price Predictions - Lancaster City Council
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc.AGIO - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc.AGIO - PR Newswire
Agios drops as FDA delays review of thalassemia drug - MSN
Agios Pharmaceuticals: Why A Delayed FDA Review Could Still Be A Positive (NASDAQ:AGIO) - Seeking Alpha
FDA Review Delay for PYRUKYND Might Change the Case for Investing in Agios Pharmaceuticals (AGIO) - Yahoo Finance
ADAR1 Capital Management LLC Acquires New Holdings in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Northern Trust Corp Has $16.88 Million Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Does Agios Pharmaceuticals Inc. outperform in volatile marketsJuly 2025 Pullbacks & High Conviction Investment Ideas - classian.co.kr
Agios Pharmaceuticals Inc.’s volatility index tracking explainedWeekly Gains Report & Weekly Setup with High ROI Potential - Newser
Statistical indicators supporting Agios Pharmaceuticals Inc.’s strengthJuly 2025 WrapUp & Free Daily Entry Point Trade Alerts - Newser
Goldman Sachs Reaffirms Their Hold Rating on Agios Pharma (AGIO) - The Globe and Mail
Is Agios Pharmaceuticals Inc. backed by strong institutional buyingQuarterly Portfolio Report & Safe Capital Growth Trade Ideas - خودرو بانک
What is Agios Pharmaceuticals Inc.’s market positionJuly 2025 Outlook & Weekly Watchlist for Consistent Profits - خودرو بانک
Goldman Sachs maintains Neutral rating on Agios Pharma stock amid FDA delay - Investing.com Canada
Liver Injury REMS Delays US FDA Approval Of Agios’s Pyrukynd In Thalassemia - insights.citeline.com
Will Agios Pharmaceuticals Inc. outperform tech stocksTrend Reversal & Daily Chart Pattern Signals - خودرو بانک
Can Agios Pharmaceuticals Inc. withstand a market correctionJuly 2025 Fed Impact & AI Enhanced Trading Signals - خودرو بانک
Agios Pharma stock faces FDA delay as PDUFA date extended for Pyrukynd - Investing.com Canada
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia - The Globe and Mail
Goldman Sachs Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Cuts Target Price to $39 - 富途牛牛
Backtesting results for Agios Pharmaceuticals Inc. trading strategiesTrade Volume Report & High Conviction Buy Zone Picks - Newser
FDA extends review period for Agios’ thalassemia drug By Investing.com - Investing.com Canada
Armistice Capital LLC Cuts Stake in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Detecting support and resistance levels for Agios Pharmaceuticals Inc.Recession Risk & Weekly High Return Forecasts - Newser
Combining machine learning predictions for Agios Pharmaceuticals Inc.Market Trend Summary & Risk Managed Trade Strategies - Newser
How institutional ownership impacts Agios Pharmaceuticals Inc. stockWeekly Profit Report & Weekly Consistent Profit Watchlists - Newser
Will Agios Pharmaceuticals Inc. stock recover after recent dropMarket Sentiment Summary & Consistent Growth Equity Picks - Newser
Liver Injury REMS Delays Agios’s Pyrukynd US FDA Approval In Thalassemia - insights.citeline.com
Agios Pharma stock falls as BofA lowers price target on PDUFA delay - Investing.com Canada
Mitapivat PDUFA for Thalassemia Delayed to December - HCPLive
Agios Pharma stock faces FDA delay as PDUFA date extended for thalassemia drug - Investing.com Canada
Agios Pharmaceuticals: New FDA Setback Likely Temporary As Issues Can Be Mitigated - Seeking Alpha
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More - Stocktwits
FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use - Benzinga
Agios Pharmaceuticals shares fall 13.52% intraday after FDA delays PDUFA target date for PYRUKYND. - AInvest
FDA delays decision on Agios drug in thalassemia over liver safety - Endpoints News
Agios Pharmaceuticals stock falls after FDA extends review of thalassemia drug - Investing.com Canada
Bank of America Securities Remains a Buy on Agios Pharma (AGIO) - The Globe and Mail
Why Did Agios Plunge 26.94%? FDA Delays PYRUKYND Review - AInvest
Agios Pharmaceuticals and the FDA Delay for Pyrukynd in Thalassemia: Assessing the Materiality of Safety Concerns and REMS Submission on Commercial Potential and Stock Valuation - AInvest
Agios stock drops as FDA delays Pyrukynd review (AGIO:NASDAQ) - Seeking Alpha
FDA extends review period for Agios’ thalassemia drug - Investing.com
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia - The Manila Times
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):